RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.